Browse the evidence

Tirzepatide treatment leads to significant weight loss in patients with hypothalamic obesity (HO) resulting from craniopharyngioma resection, despite the condition's historical resistance to standard therapies.

For patients with hypothalamic obesity due to brain tumors or surgery, standard diet and exercise often fail. Tirzepatide, a weekly injection starting at 2.5mg and increasing to 10mg, has shown significant weight loss in case reports. However, adherence is critical, as stopping the medication leads to rapid weight regain. Consult an endocrinologist to discuss if this treatment is appropriate for your specific condition.

Tirzepatide use is associated with novel safety signals including belching, upper respiratory tract infections, and postmenopausal hemorrhage, which are not prominently featured in standard prescribing information.

Be aware that Tirzepatide may be linked to new symptoms not always listed in official documents, such as excessive belching, respiratory infections, or unusual bleeding (especially in postmenopausal women). Report these to your healthcare provider, as they are emerging safety signals.

GLP-1 receptor agonist use may improve specific inflammatory or scarring alopecias (e.g., Folliculitis Decalvans, Central Centrifugal Cicatricial Alopecia) through metabolic modulation and anti-inflammatory effects.

If you have a specific type of hair loss like Folliculitis Decalvans or Central Centrifugal Cicatricial Alopecia, and you are prescribed a GLP-1 agonist for weight or diabetes, it might actually help your hair regrow by improving blood flow and reducing inflammation. This is not guaranteed for everyone, but it is a documented possibility in case studies.

A 16-week nutritional intervention combining whey protein with leucine and fish oil with vitamin D3 increases total lean mass in very old adults with low functional capacity, despite failing to improve physical performance metrics like strength or gait speed.

For very old adults with low function, a specific combination of whey protein (with leucine) and fish oil (with Vitamin D) can increase lean mass by about 0.5 kg over 4 months. However, this did not improve strength or walking speed. Adherence to the fish oil component dropped significantly over time, suggesting that simpler regimens or better palatability might be needed for long-term use.

Tirzepatide exacerbates orthostatic intolerance and causes marked tachycardia in patients with Postural Orthostatic Tachycardia Syndrome (POTS).

If you have POTS and are considering tirzepatide, discuss your specific heart rate response risks with your doctor. This case suggests that standard dosing might cause severe tachycardia in POTS patients, so a lower starting dose (e.g., 2.5 mg) and close monitoring of heart rate and orthostatic symptoms are critical to prevent exacerbation.

Tirzepatide use is associated with a potential risk of acute deep vein thrombosis (DVT), particularly in patients with predisposing risk factors such as obesity, rapid weight loss, or dehydration.

If you are taking tirzepatide, be aware of signs of blood clots like swelling, pain, or redness in your arms or legs. While rare, this risk exists, especially if you are losing weight rapidly or are obese. Report these symptoms to your doctor immediately.

Tirzepatide may trigger new-onset atrial fibrillation in susceptible individuals through autonomic activation and sinoatrial node effects, despite its overall cardiometabolic benefits.

If you start tirzepatide and feel palpitations, lightheadedness, or a racing heart, seek medical attention promptly. While the drug improves long-term metabolic health, it can increase heart rate and potentially trigger atrial fibrillation in susceptible individuals. Do not ignore new cardiac symptoms.

Coadministration of tirzepatide and SGLT2 inhibitors in Type 1 Diabetes Mellitus patients significantly increases the risk of severe euglycemic diabetic ketoacidosis (euDKA), potentially requiring mechanical ventilation.

If you have Type 1 Diabetes, do not take Tirzepatide or SGLT2 inhibitors together without extreme caution and specialist oversight. Monitor ketones daily, especially if you feel nauseous or vomit, as blood sugar may remain normal while dangerous acidosis builds up.

Timing of protein ingestion (before vs. after resistance training) does not significantly affect total body lean mass gains.

You do not need to rush to drink protein immediately after your workout. As long as you consume your protein within a few hours before or after training, your muscle growth will be the same. Focus on getting enough total protein throughout the day rather than stressing about the exact timing.

Timing of protein ingestion does not significantly affect upper body (chest press) strength gains.

For upper body exercises like chest press, it does not matter if you drink your protein before or after your workout. Your strength gains will be the same. Focus on getting enough total protein throughout the day.

The 'Lipid Theory' and 'Food Pyramid' guidelines, which recommend limiting saturated fat and increasing carbohydrates, have contributed to the 'diabesity pandemic'.

Be critical of official dietary guidelines. The paper argues that the 'Lipid Theory' and 'Food Pyramid' have contributed to the 'diabesity pandemic'. Focus on whole food sources of carbohydrates and healthy fats, and avoid processed foods and refined sugars.

High-volume static stretching is a viable therapeutic alternative or supplement for counteracting immobilization-induced muscle atrophy in patients who are bedridden, post-surgery, or have mobility restrictions.

If you are recovering from surgery or an injury and cannot lift weights, use a stretching device or manual stretching for 30 minutes to 2 hours daily. This can help prevent muscle loss during immobilization. Consult your doctor before starting.

Proximity to failure (4-6 RIR vs 1-3 RIR vs 0 RIR) does not significantly affect muscle hypertrophy (muscle thickness) in trained men over an 8-week period.

For muscle growth, it does not matter much whether you train to failure or stop with 1-3 reps left. Both approaches can yield similar hypertrophy. Focus on consistency and progressive overload rather than chasing failure on every set.

Natural peptides (BRP, BPC-157, MOTS-c) offer a safer, more metabolically specific alternative to semaglutide for obesity management by preserving lean mass and avoiding severe gastrointestinal side effects.

Natural peptides like BRP, BPC-157, and MOTS-c are emerging as potential alternatives to semaglutide, offering weight loss with better preservation of muscle mass and fewer gastrointestinal side effects. However, current evidence is limited to animal studies. Patients should consult healthcare providers regarding the safety, dosage, and regulatory status of these peptides, as they are not yet standard FDA-approved treatments for obesity.

Acute administration of GLP-1 receptor agonists reduces brain reactivity (BOLD response) to food-related cues in reward and salience regions, whereas long-term administration effects are inconsistent or attenuate over time.

GLP-1 medications appear to reduce the brain's intense reaction to food cues, particularly when taken acutely. However, this neural dampening may not persist or may vary significantly with long-term use. The evidence is currently limited and inconsistent, so while the mechanism suggests reduced craving, individual responses to long-term cue reactivity reduction are not guaranteed.

Neurokinin 2 receptor (NK2R) activation reduces appetite and body weight in mice without the gastrointestinal side effects associated with GLP-1 based treatments.

Research is exploring new drugs that target Neurokinin 2 Receptors (NK2R) to suppress appetite without causing the nausea common with current GLP-1 drugs. These are currently only proven effective in mice, so they are not yet available for human use.

Tirzepatide can cause direct drug-induced liver injury (hepatitis) independent of gallbladder disease, characterized by elevated liver enzymes and bilirubin that normalize upon discontinuation.

If you are taking Tirzepatide and experience symptoms like jaundice, dark urine, or right-sided abdominal pain, seek medical attention immediately. Your doctor should check liver enzymes. If levels are elevated, stopping the drug typically leads to full recovery within a month, but this requires prompt medical intervention and monitoring.

Tirzepatide therapy can cause euglycaemic ketoacidosis in non-diabetic patients, particularly when initiated via online prescribing without rigorous monitoring, due to starvation induced by gastrointestinal side effects.

If you are taking tirzepatide (Mounjaro) for weight loss, especially through an online service, be aware that you can develop a dangerous condition called euglycaemic ketoacidosis. This means your blood becomes acidic due to ketones, even if your blood sugar stays normal. Watch for symptoms like nausea, vomiting, abdominal pain, and fatigue. If you feel unwell, check your ketones if possible and seek medical attention immediately. Do not ignore gastrointestinal side effects as they can lead to starvation and acidosis.

Tirzepatide use is associated with a probable risk of acute pancreatitis, characterized by a strong temporal correlation between drug initiation and symptom onset, and clinical resolution upon discontinuation.

If you are taking tirzepatide and develop severe, persistent upper abdominal pain, nausea, or vomiting, stop the medication immediately and seek medical attention. Do not assume the pain is just from gallstones or indigestion, especially if it started shortly after beginning the drug. Early discontinuation can prevent severe complications.

At a population level, distributing GLP-1 medications using less frequent dosing regimens (e.g., every two weeks) allows twice as many obese adults to be treated with the same total drug supply, leading to greater reductions in national obesity rates and mortality compared to standard once-weekly dosing.

This finding is primarily for policymakers and insurers. It suggests that subsidizing GLP-1 drugs for less frequent dosing could save more lives by allowing more people to access treatment. For individual patients, this means that getting on a GLP-1 drug, even at a lower dose or frequency, is better than not getting it at all.

Modifying the physical structure of beef (minced vs. steak) while keeping nutrient composition identical does not significantly alter muscle protein synthesis (MPS) rates, but it does significantly improve whole-body net protein balance by enhancing digestion and absorption kinetics.

If you are eating enough protein (around 26g+ per meal) and engaging in resistance training, the physical form of your meat (minced vs. steak) likely does not change how much muscle you build directly. However, minced meat may be easier to digest and absorb, leading to better overall protein retention in the body, which might be beneficial for older adults or those with chewing difficulties.

Consuming soy milk as a post-resistance exercise recovery beverage produces acute circulating sex hormone profiles (testosterone, estrogen, progesterone) equivalent to dairy milk, refuting concerns that soy phytoestrogens negatively impact male anabolic potential.

If you are a male resistance trainer concerned about 'feminizing' effects, you can safely use soy milk as a post-workout recovery drink. This pilot study shows it affects your sex hormones (testosterone, estrogen, progesterone) just as much as dairy milk does, meaning it won't hinder your muscle-building efforts compared to dairy.

Replacing saturated animal fats with polyunsaturated vegetable oils (specifically linoleic acid-rich oils like safflower, canola, and hydrogenated oils) increases all-cause and cardiovascular mortality and accelerates atherosclerosis without lowering LDL-cholesterol in the long term.

Current mainstream guidelines recommending the substitution of animal fats with vegetable oils (high in linoleic acid) may be increasing health risks. The authors suggest restricting toxic vegetable oils (canola, hydrogenated oils) and increasing cholesterol and animal fat intake to non-obese levels, based on evidence that high cholesterol correlates with longevity and vegetable oils may accelerate disease via inflammatory and endocrine mechanisms.

The German Nutrition Society's (DGE) 2024 dietary guidelines, which prioritize minimizing environmental burden and deviation from current consumption over health outcomes, are methodologically flawed and potentially harmful because they significantly increase carbohydrate intake while reducing protein and fat without evidence-based justification.

Do not follow the new DGE guidelines blindly, especially if you are concerned about metabolic health, weight, or blood sugar. The guidelines significantly increase carbohydrates and decrease fats and proteins without strong evidence. Instead, focus on nutrient-dense foods, prioritize protein and healthy fats for satiety and metabolic health, and consider that local, sustainably sourced animal products can be part of a healthy and environmentally sound diet.